Limitations of the HOMA-B Score for Assessment of β-Cell Functionality in Interventional Trials—Results from the PIOglim study

Diabetes Technology and Therapeutics

Volumn 12, Issue 8, 2010, Pages 599-604

  Pfützner, Andreas ^a,b   Derwahl, Michael ^c   Jacob, Stephan ^d   Hohberg, Cloth ^a   Blümner, Ernst ^e   Lehmann, Ute ^f   Fuchs, Winfried ^f   Forst, Thomas ^a  

^a Institute for Clinical Research and Development   (Germany)

^b UNIVERSITY OF APPLIED SCIENCES   (Germany)

^c Berlin Institute for Population and Development   (Germany)

^d Diabetes Research Center   (Germany)

^e Ecron Acunova GmbH   (Germany)

^f Takeda Pharma GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; GLIMEPIRIDE; PIOGLITAZONE; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECT; FEMALE; HUMAN; INSULIN RESISTANCE; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATIENT SELECTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; PATIENT SELECTION; PROSPECTIVE STUDIES; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 77957659168     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2010.0019     Document Type: Article

References (14)

1. Matthews D, Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner RC: Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
2. Levy J.C., Matthews D.R., Hermans MP: Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 1998;21:2191-2192.
3. Wallace T.M., Levy J.C., Matthews DR: Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487-1495.
4. Pfützner A, Pfützner A.H., Larbig M, Forst T: Role of intact proinsulin in diagnosis and treatment of type 2 diabetes mellitus. Diabetes Technol Ther 2004;6:405-412.
5. Pfützner A, Kunt T, Mondok A, Pahler S, Konrad T, Luebben G, Forst T: Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes. Diabetes Care 2004;27:682-687.
6. Galloway J.A., Hooper S.A., Spradlin C.T., Howey D.C., Frank B.H., Bowsher R.R., Anderson JH: Biosynthetic human proinsulin. Review of chemistry, in vitro and in vivo receptor binding, animal and human pharmacology studies, and clinical trial experience. Diabetes Care 1992;15:666-692.
7. Pfützner A, Standl E, Hohberg C, Konrad T, Strotmann H.J., Lübben G, Pahler S, Langenfeld M, Schulze J, Forst T: IRIS II Study: intact proinsulin is confirmed as highly specific marker for insulin resistance in a cross-sectional study design. Diabetes Technol Ther 2005;7:478-486.
8. Hedblad B, Nilsson P, Janzon L, Berglund G: Relation between insulin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects. Results from a cross-sectional study in Malmã, Sweden. Diabet Med 2000;17:299-307.
9. Davies M.J., Metcalfe J, Day J.L., Grenfell A, Hales C.N., Gray IP: Effect of sulphonylurea therapy on plasma insulin, intact and 32/33 split proinsulin in subjects with type 2 diabetes mellitus. Diabet Med 1994;11:293-298.
10. Hanefeld M, Patwardhan R, Jones NP; Rosiglitazone Clinical Trials Study Group: A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes. Nutr Metab Cardiovasc Dis 2007;17:13-23.
11. Pfützner A, Schãndorf T, Seidel D, Winkler K, Matthaei S, Hamann A, Forst T: Impact of rosiglitazone on β-cell function, insulin resistance, and adiponectin concentrationsâresults from a double-blind oral combination study with glimepiride. Metabolism 2006;55:20-25.
12. Pfützner A, Wilhelm B, Forst T: Rosiglitazone and glimiperide: review on the clinical results supporting a fixed dose combination. Vasc Health Risk Manag 2007;3:211-220.
13. Pfützner A, Forst T: Pioglitazoneâan anti-diabetic drug with the potential to reduce cardiovascular mortality. Exp Opin Pharmacother 2006;7:463-476.
14. Kahn S.E., Haffner S.M., Heise M.A., Herman W.H., Holman R.R., Jones N.P., Kravitz B.G., Lachin J.M., O'Neill M.C., Zinman B, Viberti G; ADOPT Study Group: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355:2427-2443. Erratum in: N Engl J Med 2007;356:1387-1388.